Here’s a completely personal review of the past year in cardiology. Please write a comment if you strongly agree, disagree, or think something is missing.
Drug of the Year: Rivaroxaban (Xarelto)– Despite a highly negative review from FDA reviewers, rivaroxaban gained FDA approval for the coveted stroke prevention in AF indication. The drug was approved earlier in the year for VTE prevention after surgery. The biggest surprise, though, was rivaroxaban’s success in ACS in the ATLAS ACS TIMI 51 trial, which may well have an important impact on the field for years to come.
- Rivaroxaban (Xarelto) Gains First FDA Approval for DVT Prevention
- FDA Reviewers Recommend Complete Response Letter for Rivaroxaban (Xarelto)
- The Rivaroxaban FDA Panel and Large Pragmatic Trials
- Live Blog– FDA Advisory Panel on Rivaroxaban (Xarelto)
- Rivaroxaban Meets Primary Endpoint in ATLAS ACS TIMI 51
- FDA Approves Rivaroxaban for Stroke Prevention in AF
- ATLAS ACS 2-TIMI 51: Rivaroxaban Beneficial in Low-Risk ACS Population